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Background: The purpose of this study was to determine the accuracy of sentinel lymph node (SLN) biopsy with technetium 99
(99mTc) and/or blue dye-enhanced lymphoscintigraphy in vulval cancer.
Methods: Sensitive searches of databases were performed upto October 2013. Studies with at least 75% of women with FIGO
stage IB or II vulval cancer evaluating SLN biopsy with 99mTc, blue dye or both with reference standard of inguinofemoral
lymphadenectomy (IFL) or clinical follow-up were included. Meta-analyses were performed using Meta-Disc version 1.4.
Results: Of the 2950 references, 29 studies (1779 women) were included; most of them evaluated 99mTc combined with blue dye.
Of these, 24 studies reported results for SLN followed by IFL, and 5 reported clinical follow-up only for SLN negatives. Pooling of
all studies was inappropriate because of heterogeneity. Mean SLN detection rates were 94.0% for 99mTc, 68.7% for blue dye and
97.7% for both. SLN biopsy had pooled sensitivity of 95% (95% CI 92–98%) with negative predictive value (NPV) of 97.9% in studies
using 99mTc/blue dye, ultrastaging and immunohistochemistry with IFL as reference. Pooled sensitivity for SLN with clinical follow-
up for SLN-negatives was 91% (85–95%) with NPV 95.6%. Patients undergoing SLN biopsy experienced less morbidity than those
undergoing IFL.
Conclusions: Sentinel lymph node biopsy using 99mTC, blue dye and ultrastaging with immunohistochemistry is highly accurate
when restricted to carefully selected patients, within a rigorous protocol, with close follow-up and where sufficient numbers for
learning curve optimisation exist. Patients must make an informed choice between the slightly higher groin recurrence rates of
SLN biopsy vs the greater morbidity of IFL.
Vulval cancer accounts for B3–5% of all gynaecological
malignancies and 1% of all cancers in women, with an estimated
27 000 women diagnosed each year (Berek and Hacker, 2005).
Standard treatment for squamous cell carcinoma of the vulva
involves excision of the primary tumour and inguinofemoral
lymphadenectomy (IFL) in all but FIGO stage Ia or superficially
invasive disease. Groin lymph node status has been identified as
the most important factor in predicting mortality attributable to
vulval cancer (Royal College of Obstetricians and Gynaecologists,
1999). The efficacy of this treatment is good, with reported groin
recurrence rates varying between 1% and 10% (Burger et al,
1995; Bell et al, 2000). However, only a third of patients with
early-stage disease will have lymph node metastases, and the
remainder will not benefit from elective IFL while risking
significant morbidity (de Hullu et al, 2006; van der Zee et al,
2008). Complications affect over 50% of patients having IFL,
including infection of groin wounds, wound breakdown,
lymphocyst formation, lymphoedema and cellulitis (Gould
et al, 2001; Pereira de Godoy et al, 2002; Gaarenstroom et al,
2003; Beesley et al, 2007).
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Inguinofemoral lymphadenectomy is the standard of care
because unrecognised disease in the inguinofemoral lymph nodes
is usually fatal. A sentinel lymph node (SLN) refers to the first
lymph node that receives drainage directly from the primary
tumour and therefore has the highest probability of containing
metastatic disease. The SLNs can be identified by lymphoscinti-
graphy using the radioactive tracer Technetium 99 (99mTc)
and/ or with blue dye. The lymph node obtained can be examined
using standard histopathology with haematoxylin and eosin
(H&E), frozen section or enhanced testing (ultrastaging) with
serial sectioning of the lymph node and immunohistochemistry for
cytokeratins. Accurate identification of the sentinel node in early-
stage vulval cancer may potentially spare the patient from
undergoing IFL with its associated morbidity. The diagnostic
performance of SLN biopsy in the ‘real-world’ setting to guide
omission of IFL where the SLN is negative is also not fully
established, but is the subject of on-going multicentre studies
(GOG-0270 and GROINSS V11). We conducted a systematic
review to evaluate the accuracy of SLN biopsy in vulval cancer.
MATERIALS AND METHODS
Protocol development and overview. A protocol was developed
for undertaking systematic reviews of test accuracy, diagnostic and
therapeutic impact. Scoping searches for relevant systematic
reviews were conducted in MEDLINE, EMBASE and the Cochrane
Library. Systematic reviews were carried out using established
methods (Higgins and Green, 2011; Diagnostic Test Accuracy
Working Group, 2012). Presentation of results is according to the
PRISMA guidelines (Moher et al, 2009). Inclusion of studies, data
extraction and quality assessment were carried out in duplicate
using predesigned and piloted data extraction sheets with
differences resolved by consensus and/or arbitration involving a
third reviewer. A two-stage process was used, firstly by screening
titles and abstracts. For all references categorised as ‘include’ or
‘uncertain’ by both reviewers, full text was retrieved wherever
possible and final inclusion decisions were made on the full paper.
Search strategy, inclusion and exclusion criteria and quality
assessment. Comprehensive searches from the inception of database
to 25 October 2013 were conducted in MEDLINE, Embase, Science
Citation Index, the Cochrane Library, MEDION, Cochrane Database
of Systematic Reviews, Database of Abstracts of Reviews of Effects,
the Health Technology Assessment Database, Clinical Trials.com as
well as a search of internet resources (UK Clinical Research Network
Portfolio, specialist search gateways (OMNI and the National Cancer
Institute), Google and Copernic) to identify relevant published and
unpublished studies and studies in progress. Electronic searches were
supplemented by checking reference lists, handsearching the journal
Gynecologic Oncology and contact with authors of included studies
for information on any relevant published or unpublished studies.
No language restrictions were applied. Search strategies were
designed from a series of test searches and discussions of the results
of searches among the review team. Both MESH terms and text
words were used and included ‘vulva cancer’, ‘sentinel lymph node
biopsy’ and ‘lymphoscintigraphy’.
The population of interest was women with early stages of
vulval cancer: at least 75% of population with FIGO stage I and II
or TNM categories T1-2 N0 M0. We excluded studies on patients
with vulval melanomas, advanced cancer – FIGO stage IV,
inoperable tumours, tumours unsuitable for primary surgery,
patients with clinical suspicion of metastases, that is, with palpable
inguinofemoral lymph nodes, enlarged lymph nodes (41.5 cm) on
imaging or cytologically proven inguinofemoral lymph node
metastases at the start of the study. The index testing strategies
were SLN biopsy with 99mTc, blue dye or combined technique
(99mTc with blue dye), with histopathology by H&E either on
formalin-fixed or frozen sections or enhanced testing with thinner
sections and/or immunohistochemistry. Where studies reported
any of ultrastaging, serial sections, multiple slices, additional
sections or step sections, these were all classified as ‘ultrastaging’.
Studies on other imaging modalities and novel metastasis detection
techniques were excluded. Reference standard was histology of IFL
or clinical follow-up for SLN-negative patients. Outcomes of
interest were diagnostic accuracy, morbidity following SLN biopsy,
mortality and disease-free survival, quality of life, and impact on
surgeon’s and team’s skills and experience (learning curve). Studies
with nonclinical outcomes and those that reported outcomes per
groin only were excluded. Any prospective or retrospective test
accuracy study designs, studies investigating the diagnostic and
therapeutic impact with or without concurrent assessment of test
accuracy and prospective cohort studies of outcomes of patients
tested with 99mTc, blue dye or combined technique for SLN
biopsy were included. Case studies were excluded.
Study quality was assessed using standard guidelines for test
accuracy (QUADAS) and diagnostic and therapeutic impact
studies (Meads and Davenport, 2009; Whiting et al, 2010).
Statistical analysis. RevMan version 5.2 (The Nordic Cochrane
Centre, Copenhagen, Denmark) was used for statistical analyses
and Meta-Disc 1.4 (Unit of Clinical Biostatistics team of the
Ramo´n y Cajal Hospital, Madrid, Spain) was used for meta-
analysis. Sensitivity, specificity, true positives (TP), false positives
(FP), true negatives (TN) and false negatives (FN) were taken
directly from the source papers. If that was not possible, values
were calculated from data provided. Based on an investigation of
heterogeneity, summary estimates of sensitivity, specificity and
likelihood ratios (LRs) were derived as appropriate. Results were
displayed graphically on Forest and receiver operating curve
(ROC) plots. Summary SLN detection rates and their 95%
confidence intervals were calculated using Meta-Disc.
RESULTS
Characteristics of included studies. There were 2950 citations
identified from searches, of which 82 full papers were obtained and
29 relevant studies (38 publications) were included. Figure 1
displays the PRISMA diagram. Most studies were small with
o50 patients, but there were 3 larger studies with 127 patients
(Hampl et al, 2008), 452 patients (269 with tumours under 4 cm;
Levenback et al, 2012) and 403 patients (van der Zee et al, 2008).
The characteristics of the studies are presented in Supplementary
Tables 1 and 2. Patients with early-stage vulval cancer varied
between 86% and 100% of subjects, with 18 out of 29 (62%) studies
having all patients at early stage. Where reported, tumour locations
were evenly spread between midline or lateral positions. The most
commonly reported tumour types were squamous cell carcinoma.
Either TNM and FIGO staging alone or a combination of both
were given in all studies.
Index tests and histopathological techniques used for SLN
biopsy, and reference standards used in each of the studies are
summarised in Table 1. Out of 29 studies, 24 presented results for
both blue dye and 99mTc tests for SLN identification, although not
all patients underwent both tests in every study. Presentation of
results varied considerably. In 21 studies, detection rates per groin
were presented for each test separately, and both tests combined.
It is worth noting that SLN’s were always subject to rigorous
examination, whereas histopathological techniques for correspond-
ing IFL nodes were less detailed and were assumed to be H&E
unless otherwise stated.
Quality of included studies. Quality assessment is reported in
Supplementary Table 3. Of the 29 included studies, 4 had no
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information about histopathological methods (Pitynski et al, 2003;
Nyberg et al, 2007; Vakselj and Bebar, 2007; Camara et al, 2009;).
One study used frozen section as reference standard (Camara et al,
2009). In 19 studies, upon negative H&E, immunohistochemistry
using antibodies such as AE1, AE3, S-100, HMB-45, Mab, CKMNF,
CK-88 and EMA was performed. In others, additional sections/
ultrastaging was used if samples were negative by H&E staining and
standard sectioning. Thickness of slices varied between studies. Only
de Hullu et al (2000) achieved blinding of pathologists.
Test accuracy results. Reporting of results was frequently
ambiguous, making it difficult to distinguish between patients
who had no SLN detected from those with negative SLN biopsy on
histology. Results of test accuracy are presented on the basis of
detected SLN. In all, 24 studies evaluated the test accuracy of SLN
with IFL for all, and 5 studies evaluated SLN with clinical follow-up
for test-negative patients and IFL for patients with malignancy
detected in SLN biopsy (Van den Eynden et al, 2003; Terada et al,
2006; Moore et al, 2008; van der Zee et al, 2008; Achimas-Cadariu
et al, 2009). For calculation of sensitivity and specificity, studies
have been categorised into groups by the reference standards used,
the index test used and the histopathological techniques used as
follows:
1. Inguinofemoral lymphadenectomy for all
J Technetium 99 with blue dye (Supplementary Table 4)
’ Haematoxylin and eosin only or insufficient details to
determine whether immunohistochemistry or ultrasta-
ging were used
’ Immunohistochemistry
’ Frozen section only
’ Immunohistochemistry with ultrastaging
J Technetium 99 only (Supplementary Table 5)
’ Haematoxylin and eosin only or insufficient details to
determine whether immunohistochemistry or ultrasta-
ging were used
’ Immunohistochemistry
J Blue dye only (Supplementary Table 6)
’ Immunohistochemistry with ultrastaging
2. Inguinofemoral lymphadenectomy for SN positive and clinical
follow-up for SLN negative (Supplementary Table 7)
J Technetium 99 and blue dye
’ Immunohistochemistry
’ Ultrastaging
Point estimates of specificity are 100%. The ROC plane was
unhelpful and not presented. Although the point estimates of
sensitivity are close to 100%, confidence intervals were wide,
reflecting the small sample sizes available.
The SLN detection rates for each of the analysed techniques
(blue dye, 99mTc and blue dye/99mTc) are presented in Table 2.
The detection rate calculated per patient was available in all
included studies. Combined blue dye and 99mTc testing had the
highest rate of SLN detection. Pooled rates are 94.0% for 99mTc
(95% CI 90.5–96.4), 68.7% for blue dye alone (95% CI 63.1–74.0)
and 97.7 (95% CI 96.6–98.5) for 99mTc and blue dye combined.
Training and experience. Studies commonly specified the first 10
cases as learning curve (Hampl et al, 2008; van der Zee et al, 2008;
Achimas-Cadariu et al, 2009), after which SLN biopsy without IFL
could be performed. Only Levenback et al (2001) calculated that
Search results combined from databases:
(n = 2950)
Records after duplicates removed
(n = 2761)
Articles excluded (n = 49)
Duplicate (n = 2)
Inadequate intervention (n = 1)
Inadequate population (n = 10)
Inadequate study design (n =9)
Inadequate type of publication (n = 10)
Lack of data for population (n = 6)
small sample size (n = 10)
Waiting to be received (n = 1)
Studies included in synthesis = 29
(no. of publications = 38)
Articles excluded
(n = 2671)
Articles assessed for eligibility
(n = 90)
Figure 1. The PRISMA diagram for diagnostic review.
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Table 1. Studies included in the systematic review showing details of index test and reference standard
Number
Author and year
of publication 99mTc Blue dye
Both
together
Histopathological
techniques – SLN
Histopathological
techniques – remaining
nodes
Type of surgery
(or radiotherapy)
1 Achimas-Cadariu
et al (2009)
X H&E, ultrastaging NR Radical
vulvectomy (58%),
‘modified’ (41%)
2 Basta et al (2005) Xa Xa X SLN immunochemical stain for
micrometastases
NR NR
3 Brunner et al (2008) X (91%) X (9%) Frozen sections, H&E and, if
 ve, immunohistochemistry
for cytokeratins
Routine techniques NR
4 Camara et al (2009) X X X Frozen section NR NR
5 Crosbie et al (2010) X H&E and, if  ve, with
additional sections and
immunohistochemistry for
cytokeratins AE1-3
NR Radical excision
(47%), unclear
(53%)
6 de Cicco et al (2000) X H&E H&E Wide radical
excision,
hemivulvectomy
or radical
vulvectomy
7 de Hullu et al (2000) X X H&E and, if  ve, with
additional sections and
immunohistochemistry for
cytokeratins AE1-3
H&E Radical excision
(100%)
8 Hampl et al (2008) X X X H&E and, if  ve, with
additional sections and
immunohistochemistry for
panycytokeratin antibody
NR Hemivulvectomy
(35%), vulvectomy
(35%), local
tumour resection
(30%)
9 Hauspy et al (2007) X X Frozen section then serial
sections H&E and
immunohistochemistry for
cytokeratins AE1-3 for some
sections
H&E Wide local
excision (76%),
radical vulvectomy
(20%),
radiotherapy (5%)
10 Johann et al (2008) X Step sectioning Step sectioning Radical
vulvectomy (30%),
hemivulvectomy
(57%), wide
excision (13%)
11 Klat et al (2009) X H&E, ultrastaging and
immunohistochemistry for
cytokeratins AE1-3
NR Radical surgery
(100%)
12 Levenback et al
(2001)
X Frozen section if suspicious,
step sectioning and some
immunohistochemistry using
several protocols
NR NR
13 Lindell et al (2010) X (22%) X (78%) Step sections, H&E and, if
 ve, immunohistochemistry
for cytokeratin MNF116
H&E Vulvectomy (47%),
hemivulvectomy
(31%), wide local
excision (22%)
14 Louis-Sylvestre et al
(2006)
X (21%) X (79%) Serial sections, H&E and
immunohistochemistry for
cytokeratins AE1 and AE3
NR NR
15 Martinez-Palonez
et al (2006)
X 0.2mm sections, H&E and, if
 ve, immunohistochemistry
for cytokeratin and membrane
epithelial antigen
NR NR
16 Merisio et al (2005) X H&E, ultrastaging,
immunohistochemistry for
cytokeratins in 50%
Standard techniques Radical
vulvectomy or
radical vulval
excision
(percentages NR)
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the rate of SLN detection was worse in the first 2 years of the study
(failure rate 16% vs 7%).
Recurrence rates following SLN biopsy. Two groups presented
recurrences at follow-up. The first group used full IFL at initial
operation to establish diagnostic accuracy, but also presented
follow-up data (Martinez-Palonez et al, 2006; Vakselj and Bebar,
2007; Vidal-Sicart et al, 2007; Klat et al, 2009; Crosbie et al, 2010).
The second group used clinical follow-up for SLN-negative patients
to establish diagnostic accuracy (Van den Eynden et al, 2003;
Terada et al, 2006; Moore et al, 2008; van der Zee et al, 2008;
Achimas-Cadariu et al, 2009). In the first group, number of
recurrences seen (18) was less than the number of SLN-positive
patients (36) in the 4 studies that present follow-up data by SLN
status (Martinez-Palonez et al, 2006; Vakselj and Bebar, 2007;
Klat et al, 2009; Crosbie et al, 2010). The SLN-negative patients
developed recurrence in 3 of these 4 studies (Martinez-Palonez
et al, 2006; Vakselj and Bebar, 2007; Klat et al, 2009). Of these, two
studies showed a higher recurrence rate in SLN-negative patients
than in patients who underwent IFL after false-negative SLN
biopsies (Martinez-Palonez et al, 2006; Vakselj and Bebar, 2007).
This may imply a therapeutic benefit to IFL or the confounding
effect of adjuvant radiotherapy.
In the second group with clinical follow-up for SLN-negative
patients, recurrence rates for groin and distant recurrence were
calculated (Supplementary Table 7). Pooled sensitivity from
SLN with clinical follow-up (91% CI 85%–95%) is comparable
to estimates where patients received IFL as the gold standard
(pooled sensitivity of 95% (92–98%), but with a lower NPV (95.3%
vs NPV of 97.9%; see Figures 2 and 3).
Table 1. ( Continued )
Number
Author and year
of publication 99mTc Blue dye
Both
together
Histopathological
techniques – SLN
Histopathological
techniques – remaining
nodes
Type of surgery
(or radiotherapy)
17 Moore et al (2008) X H&E and ultrastaging NR Radical
vulvectomy or
radical vulval
excision
(percentages NR)
18 Nyberg et al (2007) X (20%) X (80%) Histopathology NR NR
19 Pitynski et al (2003) X (14%) X (86%) NR NR NR
20 Radziszewski et al
(2010)
X Multiple slices, H&E in 50%
slices, H&E and
immunohistochemistry in other
50% slices
H&E in 50% slices, H&E and
immunohistochemistry in
other 50% slices
NR
21 Rob et al (2007) X (27%) X (73%) Frozen section then serial
sections, H&E and
immunohistochemistry on
every third slide
H&E NR
22 Terada et al (2006) X Multiple slices, H&E and, if
 ve, immunohistochemistry
with cytokeratin antigen
NR NR
23 Vakselj and Bebar
(2007)
X NR NR Tumour excised
(100%)
24 Van den Eynden et al
(2003)
X H&E and, if  ve, ultrastaging,
and immunohistochemistry for
cytokeratins AE1 and AE3
NR NR
25 van der Zee et al
(2008)
X Frozen section or routine
histopathology, ultrastaging
H&E Radical excision
(100%)
26 Vidal-Sicart et al
(2007)
X Multiple slices, H&E and, if
 ve, H&E with
immunohistochemistry
H&E Radical
vulvectomy or
radical vulval
excision
(percentages NR)
27 Klar et al (2011) X Frozen section or routine
histopathology and, if  ve,
then ultrastaging and
immunohistochemistry with
cytokeratin
H&E Radical excision
(100%)
28 Levenback et al
(2012)
X X X H&E and, if  ve, ultrastaging
and immunohistochemistry
with cytokeratin
NR NR
29 Zekan et al (2012) X Multiple slices, H&E and, if
 ve, immunohistochemistry
with cytokeratin
H&E Radical excision
(100%)
Abbreviations: 99mTc¼ technetium 99; H&E¼ haematoxylin and eosin staining; NR¼ not recorded; SLN¼ sentinel lymph node.
aThe 99mTc and blue dye discrepant results are shown in text and table.
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Survival rates. Nine studies gave information about survival
(Martinez-Palonez et al, 2006; Terada et al, 2006; Vakselj and
Bebar, 2007; Moore et al, 2008; van der Zee et al, 2008;
Achimas-Cadariu et al, 2009; Klat et al, 2009; Crosbie et al,
2010; Oonk et al, 2010). All studies were consistent with a relatively
low survival rate for patients with groin relapse. Deaths were
reported by Achimas-Cadariu et al (2009) (12 out of 46 patients,
survival 61.2 months for whole cohort and16.2 months for
8 patients with relapse), Crosbie et al (2010) (2 out of 32 patients,
follow-up 62 months), Klat et al (2009) (1out of 23 patients,
Table 2. The SLN detection rate of blue dye, 99mTc and both
Number Study 99mTc Blue dye Both together Study characteristics
1 Achimas-Cadariu et al (2009) — — 43 Out of 46 (94%) Only SCC, early and late stages
2 Basta et al (2005) 38 Out of 39a (97%) 32 Out of 39a (82%) 38 Out of 39 (97%) Not reported, early stage
3 Camara et al (2009) 13 Out of 17 (76%) 9 Out of 17 (53%) 15 Out of 17 (88%) Mostly SCC, early and late stages
4 Crosbie et al (2010) 31 Out of 32 (97%) Only SCC, early and late stages
5 de Cicco et al (2000) 37 Out of 37 (100%) Only SCC, early and late stages
6 de Hullu et al (2000) 35 Out of 59 (60%) 59 Out of 59 (100%) Only SCC, early stage
7 Hampl et al (2008) 119 Out of 127 (94%) 80Out of127 (63%) 125 Out of 127 (98%) Mostly SCC, early and late stages
8 Hauspy et al (2007) 39 Out of 41 (95%) Mostly SCC, early and late stages
9 Johann et al (2008) 23 Out of 23 (100%) Only SCC, early stage
10 Klar et al (2011) 12 Out of 16 (75%) Only SCC, early stage
11 Klat et al (2009) 23 Out of 23 (100%) Only SCC, early stage
12 Levenback et al (2001) 46 Out of 52 (88%) Mostly SCC, early and late stages
13 Martinez-Palonez et al (2006) 27 Out of 28 (96%) Mostly SCC, early stage
14 Merisio et al (2005) 20 Out of 20 (100%) Only SCC, early stage
15 Moore et al (2008) 35 Out of 36 (97%) Only SCC, early and late stages
16 Radziszewski et al (2010) 56 Out of 62 (90%) Only SCC, early stage
17 Terada et al (2006) 21 Out of 21 (100%) Only SCC, early stage
18 Vakselj and Bebar (2007) 35 Out of 35 (100%) Mostly SCC, early stage
19 Van den Eynden et al (2003) 27 Out of 32 (84%) Mostly SCC, early stage
20 van der Zee et al (2008) 403 Out of 403 100% Only SCC, early stage
21 Vidal-Sicart et al (2007) 49 Out of 50 (98%) Mostly SCC, early and late stages
22 Zekan et al (2012) 25 Out of 25 (100%) Only SCC, early stage
Combined rates 94.0% 68.7% 97.7%
95% CI 90.5–96.4 63.1–74.0 96.6–98.5
Abbreviations: 99mTc¼ technetium 99; CI¼ confidence interval; SCC¼ squamous cell carcinoma; SLN¼ sentinel lymph node. Note that for Brunner et al (2008), Lindell et al (2010), Louis-
Sylvestre et al (2006), Nyberg et al (2007), Pitynski et al (2003), Rob et al (2007) and Levenback et al, (2012) a single test was used for a proportion of patients and a combination of tests was used
for the remainder, and hence the detection rate per patient is not specific to any single test or combination.
aThe 99mTc and blue dye discrepant results are shown in text and table.
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Figure 2. Forest plot of sensitivity of SLN biopsy in group with IFL for all, 99mTc with blue dye – ultrastaging with immunohistochemistry.
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follow-up 8–46 months), Moore et al (2008) (1 out of
35 patients died of intercurrent disease, follow-up 29 months),
Terada et al (2006) (follow-up 55 months, 2/3 node-positive
patients died of cancer), Vakselj and Bebar (2007) (6 out of
10 node-positive patients, 2 out of 25 node-negative patients,
1 died of disease at 49 months) and Vidal-Sicart et al (2007)
(1 out of 50 patients died of disease, follow-up 20 months).
The largest study presented disease-specific survival for node-
negative patients with a median follow-up of 35 months, with 202
out of 276 (73.2%) patients having at least 24 months of follow-up
(van der Zee et al, 2008). The 3-year disease-specific survival for
patients with unifocal vulval disease and negative SLN was 97.0%.
In a subsequent paper, 5-year disease-specific survival was 77.3% in
patients with positive SLN. However, survival varied depending on
the histopathology technique used; 64.9% when malignant SLN
were identified by routine pathology and 92.1% when identified by
ultrastaging, and was higher with size of SLN metastases 42mm
(Oonk et al, 2010).
Quality of life. One study (62 patients) investigating quality
of life found few differences between SLN and IFL with
EORTC QLQ-C30; only the financial difficulties scale was
statistically significantly worse in the IFL group. For the
FACT-V questionnaire, there were significantly worse results
for the contentment functional scale, and oedema, complaints
and stockings symptom scales (Oonk et al, 2009).
Adverse events. Information about adverse events was
generally poorly reported. Eight studies (Table 3) provided
data (Van den Eynden et al, 2003; Terada et al, 2006; Brunner
et al, 2008; Johann et al, 2008; Moore et al, 2008; van der Zee
et al, 2008; Achimas-Cadariu et al, 2009; Crosbie et al, 2010).
Patients undergoing IFL had worse morbidity than those
undergoing SLN alone. Definitions of morbidity are not
standardised, and therefore statistical comparisons were not
possible.
DISCUSSION
This systematic review comprises 29 studies with information
on test accuracy of 99mTc and/or blue dye identification
of SLN biopsy with reference standard of either IFL for all
(24 studies) or IFL for SLN-positive nodes (containing metastases)
and clinical follow-up for SLN-negative nodes (5 studies).
There were, in effect, three index tests (99mTc, blue dye and
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Figure 3. Forest plot of sensitivity of SLN biopsy in group with IFL for SN positive, clinical follow-up for SN negative, 99mTc and blue dye,
ultrastaging, groin and distant recurrences only* (*data from Achimas-Cadariu et al, 2009 could not be included as there were insufficient data
in paper).
Table 3. Summary of adverse events from SLN or SLN biopsy with IFL
Author and year of publication Complications SLN alone SLN biopsyþ IFL
van der Zee et al (2008); Brunner et al
(2008); Achimas-Cadariu et al (2009);
Moore et al (2008); Terada et al, 2006);
Van den Eynden et al (2003); Johann et al
(2008); Crosbie et al (2010)
Short-term
adverse eventsa
Transient lymph oedema (13%), wound breakdown (11.7%)
and wound cellulitis (4.5%)
Transient lymph oedema (39%),
postoperative groin
lymphocoele (5.5%),
cellulitis arising in the labia
majora (2.8%),
wound cellulitis (9.5%) and
seroma (4.3%),
wound breakdown (34%) and
wound cellulitis (21.3%),
cellulitis (5.9%) and lymphocele
(11.8%)
Longer-term
adverse eventsa
Lymphoedema (1.9%) and recurrent erysispelas (0.4%) Wound infection (31%),
wound dehiscence (25%),
lymphocyst (22%) and chronic
lymphoedema (16%),
lymphoedema (25.2%) and
recurrent erysipelas (16.2%)
Abbreviations: IFL¼ inguinofemoral lymphadenectomy; SLN¼ sentinel lymph node.
aAs defined by the papers.
Sentinel node biopsy in vulval cancer BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.205 2843
99mTc with blue dye) and five reference standard groups
(H&E only, insufficient details to determine histopathological
techniques used, frozen section only, immunohistochemistry,
ultrastaging and ultrastaging with immunohistochemistry).
Therefore, calculating the sensitivity and specificity of finding
metastases in a SLN biopsy compared with the reference
standard was not straightforward and no meta-analysis of all
29 studies was appropriate. Unfortunately, it was not possible to
establish the success rate of SLN detection (technical success) as
distinct from sensitivity of SLN for detection of metastatic
disease.
The largest group of studies (21 studies) using 99mTc, blue
dye and immunohistochemistry demonstrated a pooled SLN
detection rate of 97.7% (CI 96–98%) with blue dye and 99mTc,
94.0% (CI 90–96%) with 99mTc alone and 68.7% (CI 63–74%)
with blue dye alone. We could not statistically compare accuracy
of 99mTc with blue dye as there were insufficient studies of
similar clinical characteristics to be able to conduct meta-
regression. Nevertheless, these results provide evidence that a
combination of blue dye/technetium and ultrastaging is the most
accurate test. Using blue dye and technetium may also benefit the
learning curve as blue dye enables direct visualisation of the SLN
(Bass et al, 1999).
Recurrence occurred in two cohorts of patients; the first
underwent IFL and then follow-up, and the second underwent
follow-up after a negative SLN. The number of clinically
apparent recurrences at follow-up was less than the number of
SLN-positive patients. This is either because microscopic
metastases detected with sophisticated histology techniques in
SLN biopsy are less likely to be clinically significant than
those detected with standard histopathology techniques, or
because subsequent IFL and/or the subsequent adjuvant
treatment is therapeutic. It is noteworthy that nodes retrieved
as ‘sentinel’ were subject to intensive examination to detect
micrometastases, whereas nodes retrieved at subsequent IFL
were either subject to routine histopathology or details of
histopathological examination were not presented. Thus, accu-
racy results are skewed to overscoring positives for SLN or
underscoring positives for IFL. Unless both SLN and IFL
are subjected to the same technique, the true value of
micrometastases detected by ultrastaging of SLN will not be
established. This review highlights the challenges in truly
assessing the value of a test such as SLN when there is such
variability in how the nodes are examined at pathology. There is
an urgent need for consensus to define the standards of
histopathology and the need for ultrastaging. Our review did
not identify any papers that presented management of groin
lymph nodes at recurrence.
One recent systematic review has reported high rates of
detection of SLN nodes, but did not make any attempt to
stratify studies by techniques used to examine SLN or
differentiate studies based on follow-up for SLN negatives
(Hassanzade et al, 2013). The strength of the test accuracy
systematic review was the rigour of its conduct and the focus on
comparing and contrasting the different types of index test and
reference standard. The studies had considerable methodological
limitations, including lack of an adequate description of
inclusion criteria, population (especially stage of disease)
and reference standard used. Histological methods varied
considerably, particularly with regard to ‘ultrastaging/additional
sections’, and the optimum methods of examining the SLN were
unclear. The results from the two largest studies (van der Zee
et al, 2008; Levenback et al, 2012) are extremely consistent
showing FN rates of o3% in unifocal vulval tumours o4 cm in
size and supporting the use of SLN biopsy in these patients. It is
noteworthy that van der Zee et al (2008) implemented a robust
training protocol before entry for SLN biopsy. Our results
show a higher FN rate of 9% with clinical follow-up for
SLN biopsy negatives, reflecting pooled estimates from
smaller studies and highlighting the importance of the
learning curve effect. Gynaecological oncologists will value the
clinical utility of knowing the FN rate of SLN in counselling
patients.
It is also uncertain whether patients would rather risk groin
metastases by forgoing IFL if they are SLN negative. One small
study surveyed 106 patients who had undergone IFL as part of
treatment; 66% would recommend IFL if the risk of missing
metastasis from SLN biopsy was 1 in 80 and 84% would
recommend IFL if the risk of missing metastasis from SLN biopsy
was 1 in 8. Age and the presence or degree of side effects
experienced by the patients surveyed, including 39% with severe
lymphoedema and 28% with severe pain, did not affect preferences
for each procedure (de Hullu et al, 2001). Further research on
factors that influence lymphatic spread, for example, age, stage of
disease and grade of tumour and exploration of patient’s
preferences, may aid decision making in the individual patient.
Sophisticated quality-of-life studies need to investigate the impact
of SLN vs IFL in patients.
At this stage, given the relatively small numbers of studies
evaluating SLN with clinical follow-up, SLN should only be
implemented within a research protocol, for unifocal tumours
o4 cm, at selected centres with sufficient numbers and expertise
to establish quality control. Careful patient counselling is
essential, referring to the trade-off between morbidity from
lymphadenectomy and the slightly higher rate of recurrence with
SLN biopsy. Consensus standards for histopathological exam-
ination and reporting for SLN and IFL nodes are urgently
needed, particularly with regard to ultrastaging and immuno-
histochemistry protocols. Given the higher recurrence rate in
patients receiving SLN biopsy, we recommend that where
patients have opted for SLN only and have not undergone full
IFL, and the SLN is negative, they should be followed-up at close
intervals (e.g., 2-monthly for 2 years) to detect any missed groin
node metastases early, and facilitate an attempt at salvage
therapy. In the absence of data to guide optimal method of
follow-up (clinical vs imaging), careful clinical monitoring would
seem pragmatic.
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